Q32 Bio Inc: A Glimpse into the Biotechnology Sector

Q32 Bio Inc, known in the market as Homology Medicines, Inc., is a company operating within the health care sector, specifically in the biotechnology industry. The company is listed on the Nasdaq stock exchange and trades in USD. As of May 5, 2025, the close price of Q32 Bio Inc’s stock was $1.54. The company’s market capitalization stands at $19,030,000 USD.

Financial Overview

The company’s stock has experienced significant volatility over the past year. The 52-week high was recorded at $53.79 on September 10, 2024, while the 52-week low was $1.38 on April 8, 2025. The price-to-earnings ratio is currently at -0.437851, indicating that the company is not yet profitable.

Business Operations

Q32 Bio Inc specializes in genetic medicines, focusing on utilizing human hematopoietic stem cell-derived adeno-associated virus vectors. This technology is employed to treat a variety of disease-causing mutations through gene correction, insertion, and knockout. The company primarily serves patients located in the United States.

For more information, Q32 Bio Inc’s website can be accessed at www.homologymedicines.com .

This article provides a concise overview of Q32 Bio Inc’s current standing in the biotechnology sector, highlighting its financial metrics and core business operations.